OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (378)	3/13/2006 7:20:02 PM
From: DewDiligence_on_SI	of 447

Re: Macugen vs Lucentis head-to-head trial It can not be blinded, it will be hard to randomize, so why do it? It can be blinded (or “masked” as they prefer to say in ophthalmology) by giving injections on week 1,2,3,4,9,14,19, etc. In the Macugen arm, some of the first 4 weeks would be shams. The five-week interval splits the difference between the two therapies and would be good enough for a comparison trial. Moreover, if DNA’s PIER study turns out positive, a six-week instead of five-week interval can be used. Technical problems with blinding are not the main reason this trial probably won’t be run. The main reason the trial probably won’t be run is that the results would more than likely not be flattering for Macugen.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next